1Yumine K, Kawahara M. Phase 1I study of S-l, a novel oral fluorouraeil, in advanced non-small-cell lung cancer [J ]. Gan To Kagaku Ryoho, 2006, 33(1): 189.
2Kubota K, Sakai H, Yamamoto N, et al. A muhi-institution phase Ⅰ/Ⅱ trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer[J]. J Thorac Oncol. 2010. 5(5): 702.
3Okamoto I, Fukuoka M. S-1 : A New oral fluoropyrimidine in the treatment of patients with advanced non small-cell lung cancer[J]. Clinical Lung Cancer, 2009, 10(4): 290.
4Takiguchi Y, Tada Y, Gemma A, et al. Phase Ⅰ/Ⅱ study of docetaxel and S-1, an oral fluorinated pyrimidine, for un- treated advanced non-snmll cell lung cancer[J]. Lung Cancer, 2010, 68(3): 409.
5Totani Y, Saito Y, Hayashi M, et al. A phase Ⅱ study of S -1 monotherapy as second-line treatment for advanced non-small cell lung cancer [ J ]. Cancer Chemother Pharmacol,2009, 64(6): 1181.
6Segawa Y, Kiura K, Hotta K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previ- ously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 [J]. J Thorac Oncol, 2010, 5(9): 1430.
7Segawa Y, Kiura K, Hotta K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previ- ously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 [J]. J Thorac Oncol, 2010, 5(9): 1430.
8Ono A, Naito T, Murakami H, et al. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-celllung cancer[J]. Int J Clin One.l, 2010, 15(3): 161.
9Satouchi M, Kotani Y, Katakami N, et al. Randomized phase Ⅱ study of two different schedules of gemcitabine and oral S-1 in chemo-nave patients with advanced non-small cell lung cancer[J]. J Thorac Oncol, 2010, 5(5): 696.
10Ohyanagi F, Yamamoto N, Horiike A,et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non small-cell lung cancer[J]. Br J Cancer, 2009, 101(2): 225.
7Calvert H MTA a novelmultitargeted antifolate, from preclinical to phase 1 and beyond: summary and conclusions[J]. Semin Oncol, 1999, 26(Suppl 6): 105.
8Clarke S, Underhill C, White S, et al. Phase II study ofpeme -trexed and vinorelbine in patientswith locally advanced ormeta-static non small cell hmg cancer[J]. Ann Oncol, 2002, 13(Suppl 5) : 149.
9Socinski M A, Smit E F, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy naive patients with extensive stage small - cell lung cancer[J]. J Clin Oncoi, 2009, 27 (28) : 4787.
10Gmberg B H, Bremnes R M, Fhten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first - line chemotherapy in advanced non - small - cell lung cancer[J]. J Clin Oneol, 2009, 27(19) : 3217.
